U.S. Markets closed

Analysts point to potential Biogen M&A options after Alzheimer's failure

Allison DeAngelis
Analysts point to potential Biogen M&A options after Alzheimer's failure

Is Biogen continuing to strike out? Coming off the company's first earnings call since its lead Alzheimer's disease drug failed, some analysts think so.